These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. The use of palivizumab monoclonal antibody to control an outbreak of respiratory syncytial virus infection in a special care baby unit. Cox RA; Rao P; Brandon-Cox C J Hosp Infect; 2001 Jul; 48(3):186-92. PubMed ID: 11439005 [TBL] [Abstract][Full Text] [Related]
27. [Current news about epidemiology of syncytial respiratory virus infection]. Palumbo E Recenti Prog Med; 2008 May; 99(5):237-9. PubMed ID: 18581965 [TBL] [Abstract][Full Text] [Related]
28. Palivizumab efficacy in preterm infants with gestational age < or = 30 weeks without bronchopulmonary dysplasia. Grimaldi M; Gouyon B; Sagot P; Quantin C; Huet F; Gouyon JB; Pediatr Pulmonol; 2007 Mar; 42(3):189-92. PubMed ID: 17243184 [TBL] [Abstract][Full Text] [Related]
29. Severe respiratory syncytial virus bronchiolitis: epidemiologic variations associated with the initiation of palivizumab in severely premature infants with bronchopulmonary dysplasia. Grimaldi M; Gouyon B; Michaut F; Huet F; Gouyon JB; Pediatr Infect Dis J; 2004 Dec; 23(12):1081-5. PubMed ID: 15626942 [TBL] [Abstract][Full Text] [Related]
30. Palivizumab for prophylaxis of respiratory syncytial virus infections in preterm neonates. Gortner L Klin Padiatr; 2017 Sep; 229(5):259-260. PubMed ID: 28926860 [No Abstract] [Full Text] [Related]
31. Prophylaxis against respiratory syncytial virus in premature infants. IMpact-RSV Study Group. Top FH; Connor EM; Carlin DA Lancet; 2000 Mar; 355(9208):1014. PubMed ID: 10768456 [No Abstract] [Full Text] [Related]
32. High risk for RSV bronchiolitis in late preterms and selected infants affected by rare disorders: a dilemma of specific prevention. Manzoni P; Paes B; Resch B; Carbonell-Estrany X; Bont L Early Hum Dev; 2012 May; 88 Suppl 2():S34-41. PubMed ID: 22633511 [TBL] [Abstract][Full Text] [Related]
33. The impact of the recent AAP changes in palivizumab authorization on RSV-induced bronchiolitis severity and incidence. Capizzi A; Silvestri M; Orsi A; Cutrera R; Rossi GA; Sacco O Ital J Pediatr; 2017 Aug; 43(1):71. PubMed ID: 28807039 [TBL] [Abstract][Full Text] [Related]
34. Prevention of respiratory syncytial virus infection with palivizumab. Thomas M; Bedford-Russell A; Sharland M Monaldi Arch Chest Dis; 2000 Aug; 55(4):333-8. PubMed ID: 11057088 [TBL] [Abstract][Full Text] [Related]
35. Administration of palivizumab: a medical provider's perspective. Helm EA; Cummings GE; Keane V; King JC Clin Pediatr (Phila); 2003; 42(9):821-6. PubMed ID: 14686554 [No Abstract] [Full Text] [Related]
36. Palivizumab. An example of indication creep. Isaacs D BMJ; 2009 Jul; 339():b2724. PubMed ID: 19581330 [No Abstract] [Full Text] [Related]
37. Palivizumab use in preterm neonates. Kingston S; Murphy BP Ir Med J; 2010 May; 103(5):141-4. PubMed ID: 20666085 [TBL] [Abstract][Full Text] [Related]
38. [Recommendations for the prevention of respiratory syncytial virus in high-risk pediatric groups]. Janković B; Minić P; Maglajlić-Djukić S; Prekajski N Vojnosanit Pregl; 2009 Oct; 66(10):827-9. PubMed ID: 19938762 [No Abstract] [Full Text] [Related]
39. [Chemoprophylaxis with palivizumab in Andalusia (Spain). Results of the 2000-2001 respiratory syncytial virus epidemic]. Grupo de Hospitales Benazuza An Esp Pediatr; 2002 Apr; 56(4):293-7. PubMed ID: 11927095 [TBL] [Abstract][Full Text] [Related]
40. A survey of palivizumab for infants with cystic fibrosis in the UK. McCormick J; Southern KW Arch Dis Child; 2007 Jan; 92(1):87-8. PubMed ID: 17185451 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]